Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial


Niskanen L., Leiter L. A. , Franek E., Weng J., Damci T., Munoz-Torres M., ...More

EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol.167, no.2, pp.287-294, 2012 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 167 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.1530/eje-12-0293
  • Journal Name: EUROPEAN JOURNAL OF ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.287-294

Abstract

Objective: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).